임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
21건 표시
- 2상모집 중· Diabetes Mellitus, Type 2A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
리드: 노보노디스크
- 2상모집 중· Diabetes Mellitus, Type 2A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
리드: 노보노디스크
- 2상모집 중단 (진행 중)· OverweightA Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
리드: 노보노디스크
- 2상모집 중단 (진행 중)· Diabetes Mellitus, Type 2A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
리드: 노보노디스크
- 2상모집 중단 (진행 중)· Postmenopausal WomenEverolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women
협력: 노보노디스크
- 2상모집 중· Diabetes type1Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
협력: 노보노디스크
- 2상모집 중단 (진행 중)· Transthyretin Amyloid Cardiomyopathy (ATTR CM)A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
리드: 노보노디스크
- 2상모집 중· Sickle Cell DiseaseA Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
협력: 노보노디스크
- 2상모집 중단 (진행 중)· Acute Myocardial InfarctionLow-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock
협력: 노보노디스크
- 2상모집 중· Primary Hyperoxaluria Type 1Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
리드: 노보노디스크
- 2상모집 중· TBI (Traumatic Brain Injury)Growth Hormone Replacement Therapy for Retried Professional Football Players
협력: 노보노디스크
- 2상모집 중단 (진행 중)· Short Stature Children Born Small for Gestational Age (SGA)A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
리드: 노보노디스크
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.